• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Exp Nephrol . Disease severity and renal outcomes of patients with chronic kidney disease infected with COVID-19

tetano

Editor, Senior Moderator
Clin Exp Nephrol


. 2022 Mar 1.
doi: 10.1007/s10157-022-02180-6. Online ahead of print.
Disease severity and renal outcomes of patients with chronic kidney disease infected with COVID-19


Efrat Gur[SUP] 1 [/SUP], David Levy[SUP] 1 [/SUP], Guy Topaz[SUP] 1 2 [/SUP], Rawand Naser[SUP] 1 [/SUP], Ori Wand[SUP] 2 3 [/SUP], Yona Kitay-Cohen[SUP] 1 2 [/SUP], Sydney Benchetrit[SUP] 2 4 [/SUP], Erez Sarel[SUP] 5 [/SUP], Keren Cohen-Hagai[SUP] 6 7 [/SUP]



Affiliations

Abstract

Introduction: While there is evidence of the presence of the coronavirus in the kidneys and resultant acute kidney injury (AKI), information on the effect of chronic kidney disease (CKD) on COVID-19 outcomes and its pathogenesis is currently lacking.
Methods: This retrospective, observational study evaluated the outcomes of all consecutive patients hospitalized during COVID-19 outbreaks in Meir Medical Center. Serum creatinine level was assessed before hospitalization ("baseline serum creatinine") and at admission, as well as minimum and maximum serum creatinine levels during hospitalization.
Results: Among 658 patients, 152 had eGFR < 60 ml/min (termed the CKD group), 506 patients served as controls. Patients in the CKD group were older, with higher prevalence of hypertension, diabetes mellitus and atherosclerosis. Disease severity and clinical presentation of CKD group were comparable to that of control group. Odds ratio for AKI was 5.8 (95%CI 3.8-8.7; p < 0.001) in CKD group vs. control group and 3.4 (95%CI 1.1-10.8) for renal replacement therapy (p < 0.026). Among the CKD group, 32.2% died after COVID-19 infection versus 14.8% of the controls (p < 0.001). Mortality increased as CKD stage increased (14.8% in controls, 29.6% in CKD stage 3, and 39.3% in CKD stages 4 and 5, p < 0.001).
Conclusion: Despite comparable disease severity at presentation, patients with CKD had significantly more AKI events and required more renal replacement therapy during hospitalization than control patients did. Mortality increased as CKD stage increased.

Keywords: Acute kidney injury; COVID-19 outcomes; Chronic kidney disease.
 
Back
Top Bottom